oncolex logo
Utskriftsdato 7.12.2019

References on neuroendocrine tumors

About neuroendocrine tumors

  1. Modlin IM, Lye KD , Kidd M . A 5-decade analysis of 13, 715 carcinoid tumors. Cancer: 2003; 15;97(4): 934–59
  2. Cancer in Norway 2010, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway

    Etiology

  3. Toumpananakis CG, Chaplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol 2008; 103: 729–32

    Histology

  4. Hamilton SR, Aaltonen LA. WHO Classification of Tumors. Pathology and Genetics of Tumours of Digestive System. Lyon, France: IARC Press, 2000:204 

    Staging/Prognosis

  5. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35.825 cases in the United States. J Clin Oncol. 2008; 26: 3063–72

    Diagnostics

  6. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003; 348: 1134–49
  7. Betchen SA, Cirigliano M, Furth EE et al. Tubulovillous adenoma of the duodenum, a new etiology for flushing and urinary 5-HIAA elevation. DigDisSci 1998; 43: 1447–81

    Surgery

  8. van Vilsteren FG, Baskin-Bey ES, Nagorney DM et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl. 2006 Mar; 12(3): 448–56

    Drug Therapy

  9. Vilar E, Salazar R, Pérez-García J et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007; 14: 221–32

    Radiation Therapy

  10. Kwekkeboom DJ, de Herder WW, Kam BL et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007; 14: 221–32